Ölmez, O. F.Bilici, A.Gürsoy, P.Sakin, A.Korkmaz, T.Çil, I.Çakar, B.Menekse, S.Demir, T.Acıkgöz, O.Hamdard, J.2024-10-082024-10-082023-11-012531-0437https://doi.org/10.1016/j.pulmoe.2022.11.006https://hdl.handle.net/11452/46011Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib.Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (>= 934.7) SII scores. Multivariate analysis revealed that PNI >= 0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR.Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib.enPrognostic nutritional indexPredicting prognosisLymphocyte ratioStage-iChemotherapySurvivalProgressionDocetaxelOutcomesScoresNsclcAlk-positiveInflammation-based prognostic scoresTreatment responseSurvivalScience & technologyLife sciences & biomedicineRespiratory systemArticle00111005590000147848529610.1016/j.pulmoe.2022.11.006